40425_2019_723_MOESM4_ESM.jpg (74.83 kB)
Additional file 4: of Efficacy and tolerability of anti-programmed death-ligand 1 (PD-L1) antibody (Avelumab) treatment in advanced thymoma
figure
posted on 2019-10-22, 19:06 authored by Arun Rajan, Christopher Heery, Anish Thomas, Andrew Mammen, Susan Perry, Geraldine OâSullivan Coyne, Udayan Guha, Arlene Berman, Eva Szabo, Ravi Madan, Leomar Ballester, Stefania Pittaluga, Renee Donahue, Yo-Ting Tsai, Lauren Lepone, Kevin Chin, Fiona Ginty, Anup Sood, Stephen Hewitt, Jeffrey Schlom, Raffit Hassan, James GulleyFigure S3. Decrease in regulatory T cells (Tregs) (A-D) and increase in myeloid derived suppressor cells (MDSC) (E-H) following steroids in clinical responders who developed immune-related adverse events (irAEs). Patient 1 (A, E), Patient 3 (B, F), and Patient 6 (C, G) received steroids for irAEs, while patient 8 (D, H) developed clinical response but no irAE for 60âdays after documentation of response. Steroids were not used during this time frame. Dashed line denotes timing of steroids and solid line indicates time of clinical response. (JPG 74 kb)